[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depression-in-adults\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depression-in-adults":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,56,89,116,141,171,204,243,271,297,322,356,379,407],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100577061","phase-3-a-study-of-a-deuterated-psilocin-analog-cyb003-in-humans-with-major-depressive-disorder-100577061",false,"NCT06793397","A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants With Major Depressive Disorder","EMBRACE","Inclusion Criteria:\n\nParticipants must meet all the following criteria to be included in the trial:\n\n* Age18 to 85 years.\n* Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR \\[if single episode, duration of ≥4 weeks and ≤24 months\\] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.\n* Moderate to severe depression at Screening and Baseline, independently confirmed.\n* Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.\n* Participant has a body mass index (BMI) of 40 kg\u002Fm2 or less (BMI ≤40 kg\u002Fm2), inclusive, at Screening.\n* Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).\n* Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.\n* Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.\n* Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.\n* Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.\n\nExclusion Criteria\n\nParticipants with any of the following characteristics\u002Fconditions will be excluded from trial participation:\n\n* Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.\n* Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.\n* Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).\n* Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.\n* Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.\n* Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.\n* Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.\n* Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.\n* Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.\n* Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal \\[including dyspepsia or gastroesophageal reflux disease\\], hepatic, or renal disorder).\n* Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.\n* Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.\n* Participants have a presence or relevant history of organic brain disorders.\n* Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.\n* Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.\n* Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.\n* Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.\n* History of serotonin syndrome.\n* Unwilling to consent to audio and video recording of psychological support and dosing sessions.","ALL","18 Years","85 Years",{"count":21,"type":22},330,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.\n\nFor more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https:\u002F\u002Fembrace-mdd-trial.com\u002F",[28,29,30,31,32,33],"Major Depressive Disorder (MDD)","Depression in Adults","Depression - Major Depressive Disorder","Depression Disorders","Depression Disorder","Depression",[35,36,33,37,38,39,40,41,42],"MDD","Psychedelic","Major Depressive Disorder","CYB003","CYB003-001","CYB003-002","Psilocybin","psilocin-7438","RECRUITING","2026-06-29",{"date":46,"type":47},"2026-06-30","ACTUAL",{"date":49,"type":47},"2025-12-10",{"date":51,"type":22},"2027-05-08",{"name":53,"class":54},"Cybin IRL Limited","INDUSTRY",68,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":88},"100610326","the-effects-of-cognitive-behavioral-therapy-on-insulin-resistance-in-people-with-hiv-100610326","NCT07226128","The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV","A Randomized, Controlled Trial Assessing the Effects of Cognitive Behavioral Therapy to Prevent Worsening Insulin Resistance in Depressed, Virologically-Suppressed, Antiretroviral-Treated Adults With HIV","Inclusion Criteria:\n\n* HIV-1 infection, documented as listed clinically in the participant's electronic medical record by any of the following tests: (1) any licensed rapid HIV test, (2) HIV enzyme test kit at any time prior to study entry, (3) at least one detectable HIV-1 antigen, or (4) at least one detectable plasma HIV-1 RNA viral load.\n* Age ≥ 18 years.\n* Ongoing receipt of stable antiretroviral therapy of any kind for at least 180 days prior to Screening\n* Meets the depression definition for this trial:\n\n  * (1) repeat PHQ-9 ≥10100 result at the Screening Visit (suggesting moderate to severe depressive symptoms), AND\n  * (2) PHQ-9 depressive disorder diagnosis (2 or more of the 9 depressive symptoms, including depressed mood or anhedonia, present in the past 2 weeks), AND\n  * (3) functional impairment (using the tenth PHQ-9 item assessing social\u002Foccupational impairment), AND\n  * (4) no evidence that the direct physiological effects of a substance, medication, or medical condition clearly account for the depressive symptoms, AND\n  * (5) no bipolar or psychotic disorders\n\nNOTE: The use of antidepressant medications is not exclusionary.\n\n* HbA1c \\\u003C 6.5% at Screening\n* HIV-1 RNA level \\\u003C 75 copies\u002FmL at Screening\n\nNOTE: There are no CD4 cell count eligibility criteria for this trial.\n\nExclusion Criteria:\n\n* Inability to complete written, informed consent\n* Inability to read and understand English as seen on a computer screen\n* Diagnosed diabetes mellitus or any previously recorded HbA1c ≥6.5%\n* History of bipolar disorder or a psychotic disorder, including schizophrenia\n\nNOTE: Depressive disorders are not exclusionary.\n\n* Incarceration at the time of any study visit\n* Active suicidality at Entry, as determined by the patient's HIV provider or social worker following a positive response (1, 2, or 3) to PHQ-9 Item #9 and a positive response (yes) to one or more of the three questions (for Question #3, the previous attempt must be within the past 10 years) on the Patient Suicidality Form (see Appendix).\n* Diagnosed disease or process, besides HIV infection, associated with increased systemic inflammation (including, but not limited to, systemic lupus erythematosus, inflammatory bowel diseases, or other collagen vascular diseases).\n\nNOTE: Hepatitis B or C co-infections are NOT exclusionary, but treatment for hepatitis C cannot be provided during study participation\n\n* End stage renal disease requiring renal replacement therapy (dialysis, transplantation).\n* Known or suspected malignancy requiring systemic treatment within 180 days of the Entry Visit.\n\nNOTE: Localized treatment for skin cancers is not exclusionary.\n\n• Therapy for serious medical illnesses within 14 days prior to the Entry Visit\n\nNOTE: Therapy for serious medical illnesses that overlaps with a study visit will result in postponement of that study visit until the course of therapy is completed; postponement outside of the allowed study visit timeframe will result in study discontinuation.\n\n* Pregnancy or breastfeeding during the study.\n* Receipt of investigational agents, cytotoxic chemotherapy, systemic immunosuppressive therapies, systemic glucocorticoids (of any dose), or anabolic steroids at the Entry Visit\n\nNOTE: Physiologic testosterone replacement therapy or topical steroids is not exclusionary. Inhaled\u002Fnasal steroids are not exclusionary as long as the participant is not also receiving HIV protease inhibitors\n\nNOTE: Use of NSAIDS and aspirin are allowed\n\n• Active drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.",{"count":64,"type":22},150,[66],"NA","The goal of this clinical trial is to learn if depression treatment improves insulin resistance, or how the body uses insulin to lower blood sugar, in people with HIV on HIV treatment. Researchers will compare an internet-based (online) depression treatment program called cognitive behavioral therapy with depression education. In the online group, participants will undergo 9 weekly treatment sessions. The education group will receive learning materials about depression and will be monitored every month. All participants will have 4 study visits over 12 months.",[69,29,70,71],"HIV","Insulin Resistance","Cognitive Behavior Therapy",[73,74,75,76,77],"hiv","depression","insulin resistance","diabetes","cognitive behavioral therapy","2026-05-31",{"date":80,"type":47},"2026-06-02",{"date":82,"type":47},"2026-04-10",{"date":84,"type":22},"2031-06-30",{"name":86,"class":87},"Indiana University","OTHER",1,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":88},"100621627","brief-culturally-adapted-behavioral-activation-therapy-for-adults-with-depression-in-indonesian-primary-care-a-type-2-hybrid-effectiveness-implementation-trial-100621627","NCT07373080","Brief Culturally Adapted Behavioral Activation Therapy for Adults With Depression in Indonesian Primary Care: A Type-2 Hybrid Effectiveness-Implementation Trial","Hybrid Type-2 Effectiveness-Implementation Study of Brief Culturally Adapted Behavioral Activation Therapy Delivered by Primary Care Psychologists for Adults With Depression in Indonesian Primary Care Setting: A Study Protocol of Pragmatic Parallel Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n* aged 18-65 years old\n* scored 10 or above on PHQ-9\n* provide informed consent\n\nExclusion Criteria:\n\n* having diagnosis of bipolar disorder, psychotic disorders, or substance use disorders","65 Years",{"count":98,"type":22},96,[66],"This is a type-2 hybrid effectiveness-implementation study of brief culturally adapted behavioral activation for adults with depression in primary care setting. This clinical trial has two parallel aims: 1) to understand if brief culturally adapted behavioral activation therapy delivered by psychologist in primary care in individual face-to-face session is effective to reduce depressive symptoms among adult patients in Primary Healthcare Centers and 2) to test the outcome of clinical training and supervision on acceptability, feasibility, appropriateness, and fidelity of implementation of brief culturally adapted behavioral activation therapy in Primary Healthcare Centers. The main questions it aims to answer is:\n\n1\\) Is brief culturally adapted behavioral activation intervention delivered by primary care psychologist effective in reducing depressive symptoms among adult patients with depression in primary care settings and 2) Are training and supervision effective in enhancing acceptability, feasibility, appropriateness and fidelity of implementation of brief culturally adapted behavioral activation therapy for adults with depression in primary care settings?",[29],[74,103,104,105,106],"behavioral activation therapy","culturally adapted treatment","implementation science","hybrid trial","2026-05-28",{"date":109,"type":47},"2026-06-01",{"date":111,"type":47},"2026-02-11",{"date":113,"type":22},"2026-07-31",{"name":115,"class":87},"Gadjah Mada University",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":88},"100600796","telehealth-collaborative-care-model-cocm-in-lung-cancer-100600796","NCT07102147","Telehealth Collaborative Care Model (CoCM) in Lung Cancer","Increasing Adoption of a Telehealth-Delivered Collaborative Care Program for Patients With Lung Cancer: A Pilot Study","Inclusion Criteria:\n\n* Are aged 18 years or older.\n* Are currently being seen by Penn Medicine Thoracic Oncology for lung cancer treatment or survivorship care.\n* Are referred to collaborative care by a Penn Medicine Thoracic Oncology clinician for treatment of depression, anxiety, or other psycho-therapy services.\n\nExclusion Criteria:\n\n* Are already receiving psycho-therapy treatment services outside of Penn Medicine's collaborative care program, Penn Integrated Care (PIC).\n* Have a significant and\u002For untreated medical and\u002For psychiatric co-morbidity (e.g., other cancers, schizophrenia, acute suicidal and\u002For homicidal ideation) that make them ineligible for the Penn CoCM program.",{"count":124,"type":22},30,[66],"The goal of this trial is to compare the impact of two outreach strategies (high touch vs. standard outreach) on a collaborative care program delivered via telehealth to patients with lung cancer.",[128,129,29],"Lung Cancer (Diagnosis)","Anxiety",[131,129,33,132],"Lung cancer","Collaborative care","2026-05-27",{"date":107,"type":47},{"date":136,"type":47},"2025-08-18",{"date":138,"type":22},"2027-06-30",{"name":140,"class":87},"Abramson Cancer Center at Penn Medicine",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":149,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":88},"100611363","phase-1-act-for-individuals-with-mncd-and-their-care-partners-100611363","NCT07239609","ACT for Individuals With MNCD and Their Care Partners","Acceptance and Commitment Therapy for Individuals With MNCD and Their Care Partners: An In-Person and Telehealth Individual Therapy Approach","ACT","Inclusion Criteria\n\nInclusion (person with MCI or MNCD):\n\n* 18+\n* MMSE= 21-27\n* Able to communicate in English\n\nInclusion (care partner):\n\n* 18+\n* Identifies as a care partner of a person with MNCD\n* Able to communicate in English\n* MMSE= 28-30\n* Is a family member or friend of the person with MNCD\n\nExclusion Criteria\n\nExclusion (person with MCI or MNCD):\n\n* Currently in an intervention for reducing anxiety or depression related to their dementia\n* MMSE= 28+ or less than 21\n\nExclusion (care partner):\n\n* MMSE= \\\u003C28\n* Is a formal (paid) caregiver",true,{"count":151,"type":22},100,[153],"PHASE1","This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD\u002FADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.",[29,156,157],"Anxiety Disorder Generalized","Grief",[159,160,161],"Mild Cognitive Impariment","Mild Neurocognitive Disorder","Dyadic intervention","2026-05-13",{"date":164,"type":47},"2026-05-15",{"date":166,"type":47},"2026-04-01",{"date":168,"type":22},"2027-12-31",{"name":170,"class":87},"Texas Tech University",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":190,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":88},"100624962","neuroma-associated-pain-management-after-combat-related-trauma-in-ukraine-100624962","NCT07416448","Neuroma-Associated Pain Management After Combat-Related Trauma in Ukraine","Comprehensive Multicenter Study on the Management of Neuroma-Associated Pain Following Combat-Related Trauma in Ukraine","NAP-C\u002FR","Inclusion Criteria:\n\n* Age 18 years or older\n* Sustained combat-related trauma\n* Clinically significant neuroma-associated pain localized to a peripheral nerve or neuroma\n* Moderate to severe pain (score ≥ 4 on a standardized numeric pain rating scale)\n* Medically stable and able to undergo a percutaneous interventional procedure\n* Able to understand and provide written informed consent\n* Willing and able to comply with study procedures, including follow-up assessments and patient-reported outcome measures\n* May be receiving standard analgesic therapy, including opioids, if usage can be monitored\n* No planned surgical intervention at the neuroma site during the study period that could interfere with pain assessment\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnant or breastfeeding\n* Severe uncontrolled medical comorbidities that preclude safe participation\n* Active infection at or near the proposed intervention site\n* Known coagulopathy or use of anticoagulants that cannot be safely withheld\n* Previous cryoablation or radiofrequency ablation at the target neuroma within the past 6 months\n* Inability to provide informed consent or comply with study procedures\n* Participation in another interventional clinical trial that could interfere with study outcomes\n* Known allergy or intolerance to materials used during the procedures",{"count":180,"type":22},50,[66],"This multicenter interventional study in Ukraine is designed to compare the effectiveness of cryoablation and radiofrequency ablation in managing neuroma-associated pain following combat-related trauma. Adult patients with clinically significant neuropathic pain caused by neuromas will be randomly assigned to receive either image-guided cryoablation or radiofrequency ablation of the affected nerve. Cryoablation uses controlled cold temperatures to temporarily disrupt nerve conduction, while radiofrequency ablation uses thermal energy to modulate nerve function. Both interventions are minimally invasive and performed under image guidance. The study will evaluate changes in pain intensity, opioid consumption, functional outcomes, and patient-reported measures at predefined time points following the procedure. This research aims to provide evidence on which intervention is more effective in reducing pain, improving function, and minimizing the need for opioid medications in patients with combat-related neuroma pain.",[184,185,186,187,29,188,189],"Pain Management","Quality of Life","Neuroma","Functional Outcome","Neuropathic Pain","Hypoesthesia",[191,192,193,194,188],"Neuroma Pain","Combat-Related Trauma","Cryoablation","Radiofrequency Ablation","2026-02-14",{"date":197,"type":47},"2026-02-18",{"date":199,"type":47},"2026-02-05",{"date":201,"type":22},"2027-02-05",{"name":203,"class":87},"Ukrainian Society of Regional Anesthesia and Pain Therapy",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":96,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":88},"100624985","gynmdd-add-on-to-supportive-psychotherapy-in-mild-to-moderate-depression-100624985","NCT07416747","GynMDD Add-On to Supportive Psychotherapy in Mild to Moderate Depression","Multicenter Interventional Real-world Study Evaluating the Impact of the Dietary Supplement GynMDD Administered as an add-on to Supportive Psychotherapy in Patients With Mild to Moderate Depression.","SWING","Inclusion Criteria:\n\n* Adults aged 18 to 65 years, inclusive\n* The main reason for consultation is a suspected depressive episode\n* MADRS score between 15 and 34, indicating mild to moderate depression\n* No suicidal risk, defined as a score of 0 on item 10 of the MADRS scale\n* Body Mass Index (BMI) between 19 and 29 (inclusive)\n* Signed informed consent, confirming that the participant understands the purpose and requirements of the study and agrees to comply with the procedures (including scheduled supportive psychotherapy sessions)\n* Affiliation with the French national health insurance system or beneficiary of such coverage\n\nExclusion Criteria:\n\n* History of severe psychiatric disorders or currently undergoing supportive psychotherapy\n* Confirmed suicidal risk, defined as a score between 1 and 6 on MADRS item 10\n* Current treatment with antidepressants (AD)\n* MADRS score \\> 34\n* Conditions in which probiotic administration is not recommended (e.g., immunodeficiency, presence of a venous catheter)\n* Allergy to any component of the placebo or the GynMDD dietary supplement\n* Current consumption of probiotic-based dietary supplements\n* Recent infectious episodes that may require antibiotic therapy\n* Current treatment with anxiolytics\n* Long-term chronic anti-inflammatory treatment\n* Alcohol abuse, defined as a consumption of 10 standard drinks per week or more\n* Use of illicit drugs or substances of abuse\n* Inability to provide informed consent\n* Participation in another clinical study within the past 12 months\n* Pregnant or breastfeeding women\n* Patients without health insurance\n* Individuals under legal protection, guardianship, trusteeship, or any other protective measure",{"count":213,"type":22},168,[66],"The goal of this clinical trial is to learn whether the dietary supplement GynMDD, when taken as an add-on to supportive psychotherapy, can improve symptoms of mild to moderate depression in adults aged 18 to 65. The main questions it aims to answer are:\n\nDoes adding GynMDD to supportive psychotherapy lead to a greater reduction in depressive symptoms (measured by the MADRS scale) compared with supportive psychotherapy plus placebo?\n\nDoes the supplement also improve digestive well-being and influence gut microbiota profiles over the course of treatment?\n\nResearchers will compare patients receiving supportive psychotherapy + GynMDD to those receiving supportive psychotherapy + placebo to see if GynMDD provides additional benefits beyond standard care.\n\nParticipants will:\n\n* Attend regular appointments with their general practitioner\n* Complete one supportive psychotherapy session per week for 8 weeks\n* Take a daily dose of GynMDD or placebo\n* Complete weekly self-assessment questionnaires on mood, digestive symptoms, and any side effects via a mobile app\n* Provide two stool samples (at the start and end of the study) for microbiota analysis",[33,32,29],[218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233],"Gut-Brain Axis","Gut Microbiota","GynMDD","Mild Depression","Moderate Depression","MADRS","Supportive Psychotherapy","Psychotherapy","Dietary Supplement","Probiotic Supplement","Real-World Study","Mental Health","Curcumin","L-Glutamine","Randomized Controlled Trial","PHQ-9","NOT_YET_RECRUITING","2026-02-13",{"date":197,"type":47},{"date":238,"type":22},"2026-03",{"date":240,"type":22},"2027-11",{"name":242,"class":87},"Fondation FondaMental",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":149,"sex":17,"minAge":18,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":23,"phases":253,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":270},"100597174","an-iso-principle-based-music-intervention-for-reducing-stress-anxiety-and-depression-100597174","NCT07055061","An ISO Principle-Based Music Intervention for Reducing Stress, Anxiety, and Depression","ISO4SAD","Inclusion Criteria:\n\n\\- Minimum of a secondary specialized school degree (vocational college) or higher\n\nExclusion Criteria:\n\n* Self-reported current or recent use of medication or history of surgical treatment\n* Self-reported history of psychiatric disorders\n* Self-reported hearing impairments\n* Female participants who are self-reported currently pregnant or breastfeeding","60 Years",{"count":252,"type":22},2000,[66],"This study aims to evaluate the effectiveness of a music-based intervention, guided by the ISO principle, in reducing stress, anxiety and depression induced by work, family or others among adults. The ISO principle suggests that emotional regulation can be supported by gradually modifying the emotional characteristics of music to help individuals transition to a desired emotional state.\n\nParticipants in this study will be randomly assigned to either a music intervention group or a control group. The intervention group will receive personalized music playlists designed to help reduce stress, anxiety and depression. The control group will not receive any music intervention during the same period.\n\nOutcomes will be measured using self-report questionnaires assessing stress, emotional state, and well-being. The study is designed to contribute to the development of accessible, non-invasive stress management tools using music as a behavioral intervention.",[256,129,29],"Stress",[258,259,260],"music intervention","emotion regulation","ISO principle","2026-02-12",{"date":263,"type":47},"2026-02-17",{"date":265,"type":47},"2024-04-23",{"date":267,"type":22},"2026-12-12",{"name":269,"class":87},"Shanghai Mental Health Center",2,{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":250,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":281,"conditions":282,"keywords":285,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":88},"100622220","comprehensive-multicenter-study-on-the-management-of-acute-pain-following-thoracic-combat-related-trauma-in-ukraine-100622220","NCT07380789","Comprehensive Multicenter Study on the Management of Acute Pain Following Thoracic Combat-Related Trauma in Ukraine","Management of Acute Pain After Thoracic Combat Trauma: A Multicenter Study in Ukraine","CMS-APT-UA","Inclusion Criteria:\n\n* Age ≥18 years\n* Thoracic trauma from combat-related injuries\n* VNRS ≥4 for acute thoracic pain\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Severe coagulopathy\n* Infection at intervention site\n* Allergy to local anesthetics\n* Inability to perform spirometry",{"count":180,"type":22},[66],"This study is a multicenter clinical trial conducted in Vinnytsia, Rivne, and Lviv, Ukraine, focusing on the management of acute pain following thoracic injuries sustained during combat. The main purpose of the study is to evaluate and compare the effectiveness and safety of two minimally invasive procedures, cryoablation and radiofrequency ablation, in controlling severe chest pain and improving patients' recovery. Cryoablation involves applying extreme cold to specific intercostal nerves to reduce pain signals, while radiofrequency ablation uses controlled heat to achieve a similar effect. Both procedures target the nerves responsible for transmitting pain from the injured areas and are performed by experienced clinicians under careful monitoring to minimize risks. Adult patients who have experienced thoracic combat trauma and are experiencing moderate to severe pain may be eligible to participate in the study if they are able to provide informed consent and comply with the study procedures. Participants will be randomly assigned to receive either cryoablation or radiofrequency ablation. Pain intensity will be assessed before the procedure, and then again at four, twenty-four, and seventy-two hours afterward using a standardized verbal numeric rating scale. In addition to measuring changes in pain, the study will monitor opioid medication use to determine whether either procedure reduces the need for pain-relieving drugs. Mechanical pain sensitivity will be evaluated using Von Frey testing, and pulmonary function will be assessed using incentive spirometry to determine whether pain reduction improves the ability to breathe deeply and cough effectively. The impact of pain on daily activities, quality of life, and emotional well-being will also be measured using validated tools such as the LANS scale, the McGill Pain Questionnaire, and the PHQ-9 depression screening questionnaire. The study aims to provide important information on the relative benefits and risks of cryoablation and radiofrequency ablation for the treatment of acute thoracic pain, including changes in pain intensity, opioid consumption, respiratory function, and overall comfort. Potential risks associated with the procedures include temporary soreness, bruising, or rare complications, but all interventions are performed under strict safety protocols. Participation in this study may allow patients to experience better pain control, potentially reduced reliance on opioid medications, and faster recovery, while contributing valuable data that could improve pain management strategies for other patients in similar circumstances. Data collected during the study will be analyzed to compare the effectiveness of the two procedures and to identify factors that may influence outcomes, such as age, body mass index, the number of intercostal levels treated, and baseline pain scores. The study provides a structured, evidence-based approach to understanding acute pain management after thoracic combat injuries and aims to support clinicians in making informed decisions to improve patient care. For patients, families, and healthcare providers, this research offers an opportunity to participate in a carefully monitored clinical trial designed to enhance recovery and reduce suffering after serious chest trauma while advancing medical knowledge in the field of pain management.",[184,283,284,185,187,29,188,189],"Thoracic Trauma","Pulmonary Function",[286,283,193,194,287],"Acute Pain Management","Combat-Related Injury","2026-01-24",{"date":290,"type":47},"2026-02-02",{"date":292,"type":47},"2026-01-01",{"date":294,"type":22},"2026-07-01",{"name":296,"class":87},"Lviv National Medical University",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":96,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":306,"briefSummary":307,"conditions":308,"keywords":309,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":88},"100602237","pilot-study-of-brief-culturally-adapted-behavioral-activation-for-adults-with-depression-in-primary-care-setting-100602237","NCT07120893","Pilot Study of Brief Culturally Adapted Behavioral Activation for Adults With Depression in Primary Care Setting","Pilot Study Assessing Acceptability, Feasibility, and Appropriateness of Brief Culturally Adapted Behavioral Activation for Adults With Depression in Primary Care Setting","Inclusion Criteria:\n\n* scored 10 or above on PHQ-9\n* provide informed consent\n\nExclusion Criteria:\n\n* having diagnosed of bipolar disorder, psychotic disorders, or substance abuse disorders",{"count":305,"type":22},12,[66],"This is a pilot study of culturally adapted behavioral activation for adults with depression in primary care setting. As a pilot study following systematic cultural adaptation process, the purpose of this clinical trial is to understand if brief culturally adapted individual intervention based on behavioral activation, can be an acceptable, feasible, and appropriate intervention to reduce depressive symptoms among adults with depression in primary care setting. The main question it aims to answer is:\n\nIs brief culturally adapted behavioral activation intervention delivered by primary care psychologist acceptable, feasible, and appropriate as an evidence based treatment for reducing depressive symptoms among adults with depression in primary care setting?",[29],[310,311,312,313],"culturally adapted behavioral activation","depressive disorder","primary care","pilot study","2025-11-24",{"date":316,"type":47},"2025-12-01",{"date":318,"type":47},"2025-09-22",{"date":320,"type":22},"2025-12-13",{"name":115,"class":87},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":17,"minAge":330,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":333,"briefSummary":334,"conditions":335,"keywords":338,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":88},"100612785","innov5-mh-maroc-integrated-mental-health-care-for-adolescents-and-adults-in-primary-care-centers-and-schools-in-morocco-100612785","NCT07258095","INNOV5-MH-MAROC: Integrated Mental Health Care for Adolescents and Adults in Primary Care Centers and Schools in Morocco","INNOV5-MH-MAROC: Multicenter Pragmatic Randomized Controlled Trial Evaluating an Integrated Program of Five WHO Innovations in Mental Health in Morocco","INNOV5-MH","Inclusion Criteria:\n\n* Adolescents (12-17 years) and adults (≥18 years) attending participating primary care centres or high schools in Morocco.\n* Clinically significant depressive and\u002For anxiety symptoms identified by screening (PHQ-9 and\u002For GAD-7) according to study thresholds.\n* Able to understand study procedures and provide informed consent (or parental consent and adolescent assent for minors).\n* Planning to remain in the study area for at least 12 months.\n\nExclusion Criteria:\n\n* Acute psychiatric emergency requiring immediate specialised care (e.g. psychosis, high-risk suicidal crisis, severe substance use disorder).\n* Cognitive impairment or severe medical condition preventing participation in the intervention or assessments.\n* Current participation in another interventional mental health trial.\n* Any other situation judged by the investigator to make participation unsafe or inappropriate.","12 Years",{"count":332,"type":22},146,[66],"Depression and anxiety are highly prevalent among adolescents and adults in Morocco, while access to evidence-based care in primary care centers and schools remains limited. This multicenter pragmatic randomized controlled trial evaluates an integrated mental health program inspired by WHO priorities. The INNOV5 intervention combines: (1) a collaborative care model in primary care; (2) mhGAP-based task-shifting and stepped care; (3) validated digital mental health interventions; (4) virtual reality exposure therapy for selected anxiety- or trauma-related cases; and (5) a school-based mental health promotion component in participating high schools. The primary objective is to compare the change in depressive symptoms (PHQ-9) at 6 months between INNOV5 and enhanced treatment as usual (TAU+). Secondary objectives include effects on anxiety (GAD-7), quality of life (WHOQOL-BREF), suicidal ideation and behavior (C-SSRS), functioning, school attendance, and feasibility and acceptability of the program.",[336,29,129,337],"Depression in Adolescence","Mental and Behavioural Disorders",[33,129,339,340,341,342,343,344,345,346],"Adolescent mental health","Primary care","School-based mental health","Digital mental health","Virtual reality exposure","mhGAP","Task-shifting","Morocco","2025-11-20",{"date":349,"type":47},"2025-12-02",{"date":351,"type":22},"2028-03-01",{"date":353,"type":22},"2029-12-31",{"name":355,"class":87},"Swiss Medical Academy Maroc",{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":96,"enrollmentInfo":363,"targetDuration":4,"studyType":23,"phases":365,"briefSummary":366,"conditions":367,"keywords":368,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":88},"100611346","structured-group-therapy-in-reducing-depression-and-anxiety-in-pakistan-100611346","NCT07239388","Structured Group Therapy in Reducing Depression and Anxiety in Pakistan","Effectiveness of Structured Group Therapy in Reducing Depression and Anxiety Symptoms in Pakistan: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Adults (18-65 years)\n* Diagnosed with moderate to severe depression\n* Residing in urban or rural areas of Pakistan\n* Willingness to attend 12 weekly group therapy sessions and comply with the study protocol\n\nExclusion Criteria:\n\n* Severe psychiatric disorders (e.g., psychosis, bipolar disorder)\n* Ongoing substance abuse or severe substance use disorder\n* Participation in other therapeutic interventions (e.g., individual therapy or group therapy) during the study period\n* Cognitive impairments that would interfere with participation",{"count":364,"type":22},108,[66],"This study aims to assess the effectiveness of Cognitive Behavioural Therapy (CBT) and Mindfulness-Based Stress Reduction (MBSR) in group settings to reduce symptoms of depression and anxiety, enhance emotional resilience, and improve social support among Pakistani individuals struggling with these conditions.",[29,129],[33,129,369,370],"Group therapy","Social support","2025-11-15",{"date":347,"type":47},{"date":374,"type":22},"2025-11",{"date":376,"type":22},"2026-02",{"name":378,"class":87},"Pakistan Association of Cognitive Therapists",{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":96,"enrollmentInfo":385,"targetDuration":4,"studyType":23,"phases":387,"briefSummary":388,"conditions":389,"keywords":391,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":88},"100599323","comparing-the-efficacy-of-heated-yoga-and-sauna-as-a-treatment-for-depression-100599323","NCT07082998","Comparing the Efficacy of Heated Yoga and Sauna as a Treatment for Depression","Subject Characteristics\n\nInclusion Criteria:\n\n1. adults (18-65 years old)\n2. Ability to provide informed consent\n3. English language proficiency\n4. PHQ-9 score \\> 10, indicating at least moderate depressive symptoms 21\n5. Must have filled out the waiver for the community-based partners prior to enrolling in the study\\*\n6. Individuals of childbearing potential must use an acceptable form of birth control\n7. (if applicable) willingness to keep psychiatric medications and psychotherapy stable throughout the course of the study\n8. Must be able to access mindfulness app on a device (i.e., smartphone, iPad, etc.)\n9. Can travel to Breathe in Harvard Square and at least one Restore location (i.e., Hingham, Somerville, Dedham, Newton, Lynnfield)\n\nExclusion Criteria:\n\n1. Pregnant or planning to become pregnant\n2. Breast feeding\n3. Active suicidal thinking (i.e., PHQ-9 item 9 ≥1 and a positive response to C-SSRS screener items 3, 4, 5, or 6)\n4. Active eating disorders or substance use disorders within the past 12 months, as per the MINI\n5. Primary OCD or PTSD, as per the MINI\n6. History of bipolar disorder, psychotic disorders, as per the MINI\n7. ≥25% drop in PHQ-9 score from screen to baseline\n8. Under the influence or withdrawal of drugs or alcohol\n9. Positive urine toxicology screen due to illicit drug use or other exclusionary medications. (Potential false positives will be addressed on a case-by-case basis at the discretion of the PI or designee)\n10. have had a bone fracture or joint surgery in the past 6 months\n11. not able to walk freely or without difficulty\n12. any serious, unstable medical condition as determined by the revised Physical Activity Readiness Questionnaire (PAR-Q+) and do not have approval from their treating physician (we will check in with treating physician in the event that participants endorse any item on the PAR-Q+)\n13. participants must have a healthcare provider who they could contact if they needed medical care, such as a primary care doctor, a counselor, a psychiatrist, a nurse practitioner, or a clinic that you go to.\n14. Significant exposure to heated yoga classes in the past 3 months (i.e., more than 6 classes)\n15. Significant exposure to sauna sessions in the past 3 months (i.e., more than 6 sessions)\n16. Significant exposure to mindfulness app in the past 3 months (i.e., more than 6 uses of the app)\n17. are on medications that make dehydration more likely (e.g., lithium, antipsychotics, insulin-dependent) diuretics, barbiturates, b-blockers, anticholinergics, current ETOH acute intoxication, reduced ability to sweat, hemophilia, pacemaker (magnets used to assemble saunas can interrupt the pacer)\n18. antidepressant or psychiatric medications that are initiated less than 8 weeks or a dose change less than 4 weeks prior to screening visit\n19. psychotherapy that has been initiated within the past 3 months\n20. psychiatric hospitalization within the past year\n21. diagnosed with any neurological disorders that would impact participation or make participation unsafe\n22. are currently in active ketamine, Electroconvulsive therapy, or Transcranial Magnetic Stimulation treatments\n23. are unable to follow the study procedures (e.g., not able to travel to the heated yoga or sauna studios)\n24. A subject who in the opinion of the Principal Investigator would not be able to safely complete the study or would jeopardize study integrity",{"count":386,"type":22},120,[66],"This project explores whether heated yoga, sauna, and a mindfulness app reduce depressive symptoms",[31,30,32,390,33,29],"Depression Chronic",[74,392,393,394,395,396,397],"heated yoga","yoga","sauna","mindfulness","mindfulness app","clinical trial","2025-11-11",{"date":400,"type":47},"2025-11-13",{"date":402,"type":47},"2025-09-12",{"date":404,"type":22},"2027-07-31",{"name":406,"class":87},"Massachusetts General Hospital",{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":17,"minAge":330,"maxAge":413,"enrollmentInfo":414,"targetDuration":4,"studyType":23,"phases":416,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":425,"locationsCount":88},"100494023","neuro-affective-response-to-light-in-depressed-adolescents-and-young-adults-100494023","NCT05712772","Neuro-affective Response to Light in Depressed Adolescents and Young Adults","Inclusion Criteria:\n\n* Elevated Depressive Symptoms \\[PHQ9≥5 And (Item 1≥1 or Item 2≥1)\\]\n* (If \\\u003C18yr) Parent or guardian can attend the baseline clinical interview\n\nExclusion Criteria:\n\n* Unable to read and write in English\n* Intellectual disability.\n* Left or mixed handedness\n* Changes to psychotropic medication type or dosage in the past 2 months\n* Lifetime bipolar disorder or schizophrenia, or substance\u002Falcohol disorder in the past 3 months.\n* Factors influencing light and color sensitivity (i.e., color-blindness, serious ophthalmological conditions, photo-sensitizing medication).\n* Factors influencing the ability to maintain a stable sleep schedule (i.e., shift work, severe sleep disorders, extremely late or early sleep schedule).\n* Severe medical illness, neurological disorders, or history of head trauma.\n* Current pregnancy or nursing\n* MRI contraindication (e.g., metals in the body, recent tattoo, claustrophobia)\n* Positive alcohol or substance use screen at MRI visit","30 Years",{"count":415,"type":22},80,[66],"The goal of this neuroimaging pilot study is to understand developmental differences in the impact of therapeutic wavelength light (blue light) versus a non-therapeutic wavelength (red light) on emotional brain function in depression. The main questions this study aims to answer are:\n\n* Does acute exposure to blue light (vs red light) stabilize emotional brain function in depressed individuals?\n* Are stabilizing effects of blue light (vs red light) stronger for blue light in adolescents than young adults?\n\nParticipants will complete:\n\n* A magnetic resonance imaging brain scan, in which we will examine the effect of blue versus red light on emotional brain function at rest and in response to rewards and losses.\n* A pupillometry test of sensitivity to blue vs red light\n* Clinical interviews and surveys\n* Screening measures for drug and alcohol use, MRI safety, and current pregnancy \\[if relevant\\]\n* Home sleep tracking with sleep diary and actigraphy for one week",[336,29],"2025-08-05",{"date":421,"type":47},"2025-08-11",{"date":423,"type":47},"2023-06-14",{"date":113,"type":22},{"name":426,"class":87},"University of Pittsburgh"]